At Oblikue Consulting

  • we respond to health authorities' and pharmaceutical companies' current need to generate economic evidence on the therapeutic and economic value of healthcare interventions.
  • we use economic methodology and techniques to help health authorities define healthcare policies and to create market access programs fot the biotechnology industry.
  • we offer consultancy at all stages, from product pre-launch to post-launch.

 

Consultancy methods

Our consultancy methods are adapted to the needs of each client, offering personalized assistance to our customers, health authorities, and pharmaceutical companies in the generation of economic evidence on the therapeutic and economic value of healthcare interventions.

 

 

 

• Piggy-back and C/E modeling studies 

 

• Early evaluation of pricing strategies


• Environment analysis:

   - surveys of key opinion leaders or providers


• Qualitative and quantitative pricing research


Cost-of-illness studies

 

 

• Support programs for pricing and reimbursement (P&R) negotiations for news drugs

 

• Pricing strategies and value-based pricing

 

Risk Sharing Agreements

 

• Budget impact models

 

Cost-effectiveness models

 

P&R dossiers 

 

 

Risk sharing agreements

 

Economic evaluations:

   - cost-effectiveness

   - cost-utility

 

Market access support tools based on the efficiency and budget impact of news products


• Follow-up tools


 Market access plans


HTA and product reassessment support

 

 

Real-world data studies:

   - retrospective and perspective economic evaluations

   - health outcomes

   - observational studies

Comparative effectiveness studies and indirect comparison studies